Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Arm, Single Center, Phase II Clinical Study of First-line in PD1 and PARP for Maintenance Therapy for Advanced Non-small Cell Lung Cancer (Lung Squamous Cell Carcinoma)

NCT05392686 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.

NCT NCT05392686
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05392686 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Arm, Single Center, Phase II Clinical Study of First-line in PD1 and PARP for Maintenance Therapy for Advanced Non-small Cell Lung Cancer (Lung Squamous Cell Carcinoma)
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
June 20, 2022
Completion date
April 1, 2025
Enrollment
52 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer